Citadel Advisors’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-59,000
| Closed | -$2.32M | – | 15617 |
|
|
2023
Q2 | $2.32M | Sell |
59,000
-34,900
| -37% | -$1.23M | ﹤0.01% | 4900 |
|
|
2023
Q1 | $2.28M | Sell |
93,900
-85,000
| -48% | -$1.86M | ﹤0.01% | 5111 |
|
|
2022
Q4 | $3.83M | Sell |
178,900
-771,400
| -81% | -$16.5M | ﹤0.01% | 4318 |
|
|
2022
Q3 | $17M | Buy |
950,300
+826,300
| +666% | +$10.8M | ﹤0.01% | 2059 |
|
|
2022
Q2 | $1.19M | Buy |
124,000
+112,000
| +933% | +$1.41M | ﹤0.01% | 6623 |
|
|
2022
Q1 | $202K | Buy |
+12,000
| New | +$177K | ﹤0.01% | 11526 |
|
|
2021
Q4 | – | Sell |
-67,200
| Closed | -$1.09M | – | 15142 |
|
|
2021
Q3 | $1.09M | Buy |
67,200
+38,800
| +137% | +$422K | ﹤0.01% | 7920 |
|
|
2021
Q2 | $179K | Sell |
28,400
-219,700
| -89% | -$1.42M | ﹤0.01% | 12294 |
|
|
2021
Q1 | $1.53M | Buy |
248,100
+171,000
| +222% | +$1.04M | ﹤0.01% | 7041 |
|
|
2020
Q4 | $533K | Sell |
77,100
-11,300
| -13% | -$72.3K | ﹤0.01% | 8029 |
|
|
2020
Q3 | $499K | Buy |
88,400
+78,200
| +767% | +$373K | ﹤0.01% | 7309 |
|
|
2020
Q2 | $52K | Sell |
10,200
-600
| -6% | -$2.5K | ﹤0.01% | 9287 |
|
|
2020
Q1 | $37K | Buy |
+10,800
| New | +$63.1K | ﹤0.01% | 9141 |
|
|
2018
Q1 | – | Sell |
-20,100
| Closed | -$63K | – | 8953 |
|
|
2017
Q4 | $63K | Buy |
20,100
+4,200
| +26% | +$11.8K | ﹤0.01% | 7561 |
|
|
2017
Q3 | $45K | Buy |
15,900
+800
| +5% | +$2.16K | ﹤0.01% | 7206 |
|
|
2017
Q2 | $39K | Sell |
15,100
-12,300
| -45% | -$33.5K | ﹤0.01% | 7159 |
|
|
2017
Q1 | $100K | Sell |
27,400
-112,200
| -80% | -$474K | ﹤0.01% | 6865 |
|
|
2016
Q4 | $674K | Buy |
139,600
+105,800
| +313% | +$3.14M | ﹤0.01% | 4446 |
|
|
2016
Q3 | $1.56M | Buy |
33,800
+17,700
| +110% | +$998K | ﹤0.01% | 3256 |
|
|
2016
Q2 | $822K | Buy |
16,100
+5,500
| +52% | +$273K | ﹤0.01% | 3809 |
|
|
2016
Q1 | $448K | Buy |
10,600
+6,600
| +165% | +$336K | ﹤0.01% | 4565 |
|
|
2015
Q4 | $314K | Sell |
4,000
-10,500
| -72% | -$607K | ﹤0.01% | 5155 |
|
|
2015
Q3 | $588K | Sell |
14,500
-700
| -5% | -$37.1K | ﹤0.01% | 4568 |
|
|
2015
Q2 | $791K | Sell |
15,200
-9,900
| -39% | -$492K | ﹤0.01% | 4300 |
|
|
2015
Q1 | $1.17M | Buy |
25,100
+6,600
| +36% | +$343K | ﹤0.01% | 3740 |
|
|
2014
Q4 | $830K | Sell |
18,500
-14,000
| -43% | -$588K | ﹤0.01% | 4004 |
|
|
2014
Q3 | $1.26M | Buy |
32,500
+15,400
| +90% | +$604K | ﹤0.01% | 3420 |
|
|
2014
Q2 | $724K | Buy |
+17,100
| New | +$627K | ﹤0.01% | 3905 |
|
Citadel Advisors's ISEE Position: Q3 2023 in Review
Citadel Advisors sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q3 2023, closing a stake of 299,796 shares — an estimated $11.8M sold.
Citadel Advisors first reported a position in ISEE in Q3 2013 and held it in 30 quarters. The position peaked at $45.9M in Q3 2022. 0 funds tracked by Wall St. Rank hold ISEE as of Q3 2023.
- Citadel Advisors reported no remaining IVERIC bio, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- Citadel Advisors sold 299,796 IVERIC bio, Inc. Common Stock shares in Q3 2023, an estimated $11.8M.
- Citadel Advisors first reported a position in IVERIC bio, Inc. Common Stock in Q3 2013 and held it in 30 quarters.
- Citadel Advisors's IVERIC bio, Inc. Common Stock position peaked at $45.9M in Q3 2022.
- 0 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q3 2023.
Based on Citadel Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.